Careers Contact
Careers Contact

Platform

Evaxion’s pioneering AI-Immunology™ platform accelerates fast and effective vaccine target discovery, drug design, and development. Using the power of AI, our platform simulates the human immune system and generates predictive models to identify and develop personalized and other next-generation immunotherapies for patients.

About AI-Immunology™

Evaxion is a pioneering TechBio company with a leading AI–platform, AI-Immunology™, for fast and effective vaccine target discovery, drug design and development. AI-Immunology™ is clinically validated and can identify therapeutically relevant vaccine targets for cancer and infectious diseases.

AI-Immunology™ allows for ground-breaking development of novel personalized and precision vaccines for cancer and infectious diseases. The platform consists of a collection of unique in-house developed AI building blocks that can be intelligently combined to generate tailored AI prediction models addressing complex immune-related healthcare issues.

The power of AI-Immunology™ in vaccine target discovery, drug design and development

0

clinical trials confirm predictive capabilities and link to outcomes

0HRS

to complete target discovery

0%

fewer targets needs testing

0%+

on average cheaper target discovery versus reverse vaccinology

0%

vaccine target hit-rate

0

different modalities (protein, DNA, mRNA, peptides)

0+

different diseases can be addressed

About PIONEER™

PIONEER™ is a proprietary AI-Immunology™ model for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI-Immunology™ platform, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.

About ObsERV™

ObsERV™ is a proprietary AI-Immunology™ model that rapidly can be used in personalized cancer immunotherapies to complement neoantigens. We have developed a bioinformatics model that can identify endogenous retrovirus (ERVs) based on sequencing data and design a personalized ERV antigen treatment. We have proof of concept that our method works in preclinical models.

About EDEN™

EDEN™ is a proprietary AI-Immunology™ model that rapidly identifies vaccine targets – the parts of a pathogen – that can trigger a sufficient immune response. With EDEN™, we are able to identify the most protective vaccine targets of pathogens faster and at a lower cost than current state-of-the-art methods. This is a novel approach to vaccine development and holds the  potential to combat the rising global issue of bacterial antibiotic resistance and viral strain divergence.

About RAVEN™

RAVEN™ is a proprietary AI-Immunology™ model that rapidly identifies vaccine candidates against existing, emerging, and mutating viral diseases. We are developing next-generation vaccine candidates that aim to trigger a potent B- and T-cell response simultaneously. Current vaccines against viral disease are challenged by fading efficacy and evasion by mutating viruses. With RAVEN™, the addition of the T-cell component is designed to secure a broader, more durable protection.